| 1 |
34940072 | Pegylated Liposomal Doxorubicin (Caelyx®) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial. | 2021 Dec 7 |
1 |
| 2 |
31811505 | Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older. | 2020 Feb |
2 |
| 3 |
32866625 | A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials. | 2020 Dec |
1 |
| 4 |
30147088 | Breast cancer in a tertiary cancer center in India - An audit, with outcome analysis. | 2018 Jan-Mar |
2 |
| 5 |
28625777 | Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. | 2017 Sep |
1 |
| 6 |
27486994 | Guideline Adherence Regarding the Use of Expensive Drugs in Daily Practice: The Examples of Trastuzumab in Breast Cancer and Bortezomib in Multiple Myeloma. | 2016 |
1 |
| 7 |
25713436 | Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. | 2015 Apr 1 |
1 |
| 8 |
25964557 | Aquaporin 3 Expression Predicts Survival in Patients with HER2-positive Early Breast Cancer. | 2015 May |
1 |
| 9 |
26091608 | The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer. | 2015 Jun |
1 |
| 10 |
26321480 | Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications. | 2015 Nov |
1 |
| 11 |
24107908 | Prognostic factors for recurrence-free survival in patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab. | 2013 |
2 |
| 12 |
22300778 | Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. | 2012 Feb |
1 |
| 13 |
20351072 | Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. | 2010 Nov |
1 |